|本期目录/Table of Contents|

应用iTRAQ技术筛选不同生存期食管癌患者的血清差异蛋白

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3611-3616
栏目:
论着(胸部肿瘤)
出版日期:
2019-09-08

文章信息/Info

Title:
Screening of serum differential proteins in esophageal cancer patients with different survival time by using iTRAQ technology
作者:
马晓丽;?刘 娟;?曹雷雨;?张建清;?张 倩;?张 莉
新疆医科大学第一附属医院内科VIP,新疆 乌鲁木齐 830054
Author(s):
Ma Xiaoli;?Liu Juan;?Cao Leiyu;?Zhang Jianqing;?Zhang Qian;?Zhang Li
VIP Department of Internal Medicine,The First Affiliated Hospital of Xinjiang Medical University,Xinjiang Urumqi 830054,China.
关键词:
食管鳞癌;?蛋白质组学;?放化疗;?生存;?预后
Keywords:
esophageal squamous cell carcinoma;?proteomics;?radiotherapy and chemotherapy;?survival;?prognosis
分类号:
R735.1
DOI:
10.3969/j.issn.1672-4992.2019.20.014
文献标识码:
A
qq自动领红包软件:
目的:应用同位素标记相对和绝对定量(iTRAQ)技术筛选血清差异蛋白,为临床个性化治疗和判断疾病的预后提供参考依据。方法:选取确诊为局部晚期和晚期食管鳞癌患者52 例,进行常规放疗和化疗,观察疗效并随访,随访时间截止至2018年04月。根据不同生存期进行分组,应用iTRAQ技术筛选与食管癌患者生存期长短有关系的血清差异蛋白。观察这些差异蛋白的生物学特点,利用KEGG数据库将与肿瘤生存相关的优势蛋白筛选出来。结果:将不同生存期食管癌患者之间的血清差异蛋白筛选出来之后,发现有42个差异性表达明显的蛋白,分为表达上调的蛋白和表达下调的蛋白,分别是19个和23个。此外还有4个血清差异蛋白同时出现在两组间,包括1个同时上调蛋白和3个同时下调蛋白,分别是血清淀粉样A-2蛋白质(SAA2)和血浆丝氨酸蛋白酶抑制剂(SERPINA5)、组蛋白H4(HIST1H4A)以及组蛋白H3.1(HIST1H3A)。SERPINA5与生存期较长相关;HIST1H4A、HIST1H3A出现在生存期较短的一组中。KEGG数据库的分析发现,在Viral carcinogenesis、Transcriptional misregulation in cancer信号通路的调节中可能有H4、H3.1的参与。结论:在局部晚期或晚期食管鳞癌患者外周血中筛选出的一些潜在优势蛋白,经过研究发现其与食管鳞癌患者生存期长短有关,并参与一些关键通路。对食管鳞癌预后风险判断具有潜在预测价值的有HIST1H4A、HIST1H3A和SERPINA5。
Abstract:
Objective:To screen serum differentially expressed proteins by using isotope labeled relative and absolute quantitative (iTRAQ),which is closely related to the survival time of esophageal cancer,and to provide a reference for individualized treatment and prognosis of esophageal cancer.Methods:A total of 52 patients with locally advanced and advanced esophageal squamous cell carcinoma were enrolled in this study.The patients were treated with conventional radiotherapy and chemotherapy then the therapeutic effect was observed and evaluated and long-term follow-up was maintained.The survival time after radiotherapy and chemotherapy was determined,and the follow-up time ended to April 2018.Grouping according to different lifetimes and applying iTRAQ technology to filter serum differentially expressed proteins associated with survival time of esophageal carcinoma.Then the biological characteristics of these differently expressed proteins were analyzed and the dominant proteins related to tumor survival were screened out by using KEGG database.Results:After screening the serum differential proteins between different survival periods of esophageal cancer patients,42 differentially expressed proteins were found,which were up-regulated proteins and down-regulated proteins.The numbers were 19 and 23,respectively.In addition,there were 4 serum differential proteins in both groups,which included one up-regulated protein and three down-regulated proteins.SAA2 serum amyloid A-2 protein and SERPINA5 plasma serine protease inhibitor,HIST1H4A histone H4 and HIST1H3A histone H3.1.SERPINA5 was associated with a longer survival period,while HIST1H4A,HIST1H3A appeared in a shorter group.According to the analysis of KEGG database,the regulation of viral carcinogenesis,transcriptional misregulation in cancer signaling pathway may involve H4,H3.1.Conclusion:Some potential predominance proteins in peripheral blood of patients with locally advanced or advanced esophageal squamous cell carcinoma were found to be related to the survival time of esophageal squamous cell carcinoma and involved in some key pathways.HIST1H4A,HIST1H3A and SERPINA5 have been found to be of potential prognostic value in judging the prognostic risk of esophageal squamous cell carcinoma (ESCC).

参考文献/References

[1] Mcguire S.International agency for research on cancer[J].Adv Nutr,2016,7(2):418-419.
[2]Ferlay J,Hairim S,Bray F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.
[3] Enzinger PC,Mayer RJ.Esophageal cancer[J].N Eng J Med,2003,349(23):2241.
[4]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].Ca A Cancer J for Clinicians,2016,66(2):115-132.
[5]Smyth EC,Lagergren J,Fitzgerald RC,et al.Oesophageal cancer[J].Nature Reviews Disease Primers,2017(3):17048.
[6] Zhang J,Zhi C,Zhen F,et al.iTRAQ-based quantitative proteomic analyses of high grade esophageal squamous intraepithelial neoplasia[J].Proteomics Clin Appl,2017(11):11-12.
[7] Guo J,Jing R,Zhong JH,et al.Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics[J].Oncotarget,2017,8(37):62011-62028.
[8] Wang L,Chai L,Ji Q,et al.Forkhead box protein C1 promotes cell proliferation and invasionin human cervical cancer[J].Mol Med Rep,2018,17(3):4392-4398.
[9] WANG Lin,FAN Qingxia,DU Yabing.Efficacy of three chemotherapy regimens for advanced esophageal cancer[J].Chinese General Practice,2011,14(11):1250-1252.[王琳,樊青霞,杜雅冰.晚期食管癌三种化疗方案的疗效对比分析[J].中国全科医学,2011,14(11):1250-1252.]
[10]Yoshikawa R,Tsujimura T,Tao L,et al.CD44 expression is associated with unfavorable prognosis in esophageal cancer patients undergoing neoadjuvant chemoradiotherapy[J].Cancer Research,2009,69(9):18-22.
[11]Sugase T,Takahashi T,Serada S,et al.SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal squamous cell carcinoma[J].Cancer Res,2017,77(24):6975-6986.
[12]Tamaoki M,Komatsuzaki R,Komatsu M,et al.Multiple roles of SIM2 in esophageal squamous cell carcinoma and its clinical implications[J].Cancer Sci,2018(3):89.
[13]Shigaki H,Baba Y,Watanabe M,et al.PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma[J].Clin Cancer Res,2013,19(9):2451-2459.
[14]Geiger M,Zechmeister-Machhart M,Uhrin P,et al.Protein C inhibitor (PCI)[J].Immunopharmacology,1996,32(1-3):53-56.
[15]Asanuma K,Yoshikawa T,Hayashi T,et al.Protein C inhibitor inhibits breast cancer cell growth,metastasis and angiogenesis independently of its protease inhibitory activity[J].International Journal of Cancer,2007,121(5):955-965.
[16]Wakita T,Hayashi T,Nishioka J,et al.Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma[J].International Journal of Cancer,2004,108(4):516-523.
[17]Bijsmans ITGW,Smits KM,De Graeff P,et al.Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors[J].Modern Pathology,2011,24(3):463-470.
[18] Juliano CN,Izetti P,Pereira MP,et al.H4K12 and H3K18 acetylation associates with poor prognosis in pancreatic cancer[J].Appl Immunohistochem Mol Morphol,2016,24(5):337-344.
[19] Allam R,Kumar SV,Darisipudi MN,et al.Extracellular histones in tissue injury and inflammation[J].J Mol Med (Berl),2014,92(5):465-472.
[20] Klein B,Lutz-Meindl U,Kerschbaum HH.From the nucleus to the plasma membrane:translocation of the nuclear proteins histone H3 and lamin B1 in apoptotic microglia[J].Apoptosis,2014,19(5):759-775.
[21] Kremer A,Wilkowski R,Holdenrieder S,et al.Nucleosomes in pancreatic cancer patients during radiochemotherapy[J].Tumour Biol,2005,26(1):44-49.
[22] Mueller S,Holdenrieder S,Stieber P,et al.Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments[J].BMC Cancer,2006(6):143.
[23] Kremer A,Holdenrieder S,Stieber P,et al.Nucleosomes incolorectal cancer patients during radiochemotherapy[J].Tumour Biol,2006,27(5):235-242.

备注/Memo

备注/Memo:
National Natural Science Foundation of China(No.81460754);国家自然科学基金资助项目(编号:81460754)
更新日期/Last Update: 1900-01-01